These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 3924065)

  • 1. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
    Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
    Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia.
    Taskinen MR; Nikkilä EA
    Atherosclerosis; 1988 Feb; 69(2-3):249-55. PubMed ID: 3279968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of type III hyperlipoproteinemia with four different treatment regimens.
    Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB
    Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
    Rössner S; Orö L
    Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia.
    Larsen ML; Illingworth DR; O'Malley JP
    Atherosclerosis; 1994 Apr; 106(2):235-40. PubMed ID: 8060383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
    Sirtori M; Montanari G; Gianfranceschi G; Malacrida MG; Battistin P; Morazzoni G; Tremoli E; Colli S; Maderna P; Sirtori CR
    Atherosclerosis; 1983 Nov; 49(2):149-61. PubMed ID: 6365105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison between nicotinic acid and acipimox in hypertriglyceridaemia--effects on serum lipids, lipoproteins, glucose tolerance and tolerability.
    Tornvall P; Walldius G
    J Intern Med; 1991 Nov; 230(5):415-21. PubMed ID: 1940776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia.
    Illingworth DR; O'Malley JP
    Metabolism; 1990 Apr; 39(4):403-9. PubMed ID: 2182974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia.
    Hoogwerf BJ; Peters JR; Frantz ID; Hunninghake DB
    Metabolism; 1985 Oct; 34(10):978-81. PubMed ID: 4046841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrate.
    Brook JG; Lavy A; Aviram M; Zinder O
    Atherosclerosis; 1980 Aug; 36(4):461-9. PubMed ID: 7417365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a phase IV study carried out with acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia.
    Lavezzari M; Milanesi G; Oggioni E; Pamparana F
    J Int Med Res; 1989; 17(4):373-80. PubMed ID: 2676653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
    Schwandt P; Weisweiler P; Drosner M; Janetschek P
    Atherosclerosis; 1982 Apr; 42(2-3):245-9. PubMed ID: 7073803
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition.
    Föger B; Tröbinger G; Ritsch A; Lechleitner M; Hopferwieser T; Menzel HJ; Utermann G; Pfeiffer KP; Patsch JR
    Atherosclerosis; 1995 Oct; 117(2):253-61. PubMed ID: 8801871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia.
    Nikkilä EA; Huttunen JK; Ehnholm C
    Metabolism; 1977 Feb; 26(2):179-86. PubMed ID: 834151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial.
    Koev D; Zlateva S; Susic M; Babic D; Profozic V; Skrabalo Z; Langrová H; Cvrkalová AL; Rajecová E; Klimes I
    Diabetes Care; 1993 Sep; 16(9):1285-90. PubMed ID: 8404433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
    Fulcher GR; Catalano C; Walker M; Farrer M; Thow J; Whately-Smith CR; Alberti KG
    Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial.
    Crepaldi G; Avogaro P; Descovich GC; Di Perri T; Postiglione A; Sirtori CR; Strano A; Ventura S; Musatti L
    Atherosclerosis; 1988 Mar; 70(1-2):115-21. PubMed ID: 3281679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.